Jenburkt Pharmaceuticals Share Price
Small Cap | Pharmaceuticals and health care | BSE: 524731
₹957.70 -0.50 (-0.05 %)
Last Updated: 13 Mar 2025 12:00 AM
Overview
Open (₹) 970.00
High (₹) 992.95
Low (₹) 951.20
Prev. Close (₹) 958.20
Volume 719
VWAP (₹) 946.02
ROCE (%) 23.83
Industry P/E 43.95
TTM P/E 13.46
P/B Ratio 2.92
Market Cap (₹) Cr.422.66
Dividend Yield (%)1.60
EPS (₹) 58.86
ROE17.92%
Sales Growth (%) 3.82
Profit Growth (%)5.57
Day Range
992.95992.95
52 Week Range
660.051,375.00
Historical Returns
Returns (6M)
-15.14 %
Returns (1Y)
36.79 %
Returns (3Y)
74.76 %
Returns (5Y)
201.69 %
Returns (6M)
-15.14 %
Returns (1Y)
36.79 %
Returns (3Y)
74.76 %
Returns (5Y)
201.69 %
SWOT Analysis
- Price above the pivot point indicates bullish sentiment.
Technicals
Technical Rating
RSI 37.78
MFI 42.70
ATR 62.61
Commodity Channel Index -130.00
ROC125 -17.57
ROC21 -16.76
Williams %R -99.39
Resistance & Support
Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
---|---|---|---|---|---|---|---|
Current | 963.14 | 988.22 | 1,001.44 | 949.92 | 924.84 | 911.62 | 886.54 |
Week Ago | 1,024.16 | 1,044.03 | 1,058.06 | 1,010.13 | 990.26 | 976.23 | 956.36 |
Month Ago | 1,251.46 | 1,304.73 | 1,385.46 | 1,170.73 | 1,117.46 | 1,036.73 | 983.46 |
EMA & SMA
957.70
Current Price
Bullish Moving Averages
0
Bearish Moving Averages
20
5 Day 987.33
9 Day 996.34
10 Day 1001.16
12 Day 1019.43
14 Day 1028.08
20 Day 1055.71
26 Day 1085.14
50 Day 1156.11
100 Day 1141.41
200 Day 1039.88
Deals & Announcements
Bulk and Block Deals
Client Name | Deal Type | Action | Date | Avg. Price | Quantity | Exchange |
---|---|---|---|---|---|---|
JENBURKT PHARMACEUTICALS LTD | bulk | Buy | 06 Jan, 2023 | ₹649.97 | 47,037 | BSE |
ARIES STOCKTRADES PVT LTD A/C-PMS | bulk | Sell | 25 Aug, 2020 | ₹410.39 | 26,000 | BSE |
Insider Trading
Date | Name | Action | Avg. Price | Quantity | Deal Value |
---|---|---|---|---|---|
14 Jun, 2024 | PRAKASH H. Bhuta | Disposal | ₹804.79 | 20,473 | BSE |
27 Mar, 2024 | Prakash Bhuta | Disposal | ₹702.21 | 5,931 | BSE |
10 Jul, 2023 | MAHESH H BHUTA | Disposal | ₹ | 2,500 | BSE |
10 Jul, 2023 | MAHESH H BHUTA | Acquisition | ₹ | 2,500 | BSE |
10 Jul, 2023 | MAHESH H BHUTA | Disposal | ₹716.05 | 1,000 | BSE |
29 May, 2023 | RIDDHI HARESH SHROFF | Acquisition | ₹ | 14,707 | BSE |
29 May, 2023 | RIDDHI HARESH SHROFF | Disposal | ₹ | 14,707 | BSE |
26 Apr, 2023 | RIDDHI HARESH SHROFF | Acquisition | ₹ | 14,707 | BSE |
26 Apr, 2023 | RIDDHI HARESH SHROFF | Disposal | ₹ | 14,707 | BSE |
11 Nov, 2022 | RIDDHI HARESH SHROFF | Acquisition | ₹ | 14,707 | BSE |
Corporate Actions
Announcement Date | Subject | Ex - Date | Record Date |
---|---|---|---|
28 May, 2024 | Rs.15.3000 per share(153%)Dividend | 23 Jul, 2024 | 01 Jan, 1970 |
23 May, 2023 | Rs.14.4000 per share(144%)Dividend | 19 Jul, 2023 | 01 Jan, 1970 |
27 May, 2022 | Rs.12.0000 per share(120%)Final Dividend | 21 Jul, 2022 | 01 Jan, 1970 |
Announcements
Date | Source | Detail |
---|---|---|
03 Mar, 2025 | BSE India | Intimation of acquisition of land close to the existing plant at Sihor, Gujarat. |
28 Jan, 2025 | BSE India | Integrated Filing (Financial) for the quarter and nine months ended on 31st December, 2024. |
28 Jan, 2025 | BSE India | Standalone Unaudited Financial Results for the quarter and nine months ended on 31st December, 2024. |
28 Jan, 2025 | BSE India | Outcome of the Board Meeting held today on 28th January, 2025, inter-alia to approved standalone unaudited financial results for the quarter and nine months ended on 31st December,2024. |
20 Jan, 2025 | BSE India | JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 ,inter alia, to consider and approve unaudited financial results for the quarter and nine months ended on 31st December, 2024. |
05 Nov, 2024 | BSE India | Outcome of Board Meeting held today on 05-11-2024, inter-alia to approved Standalone Unaudited Financial Results For The Quarter and half year Ended On 30Th September, 2024. |
05 Nov, 2024 | BSE India | standalone Unaudited Financial Results for the quarter and half year ended on 30th September, 2024. |
28 Oct, 2024 | BSE India | JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2024 ,inter alia, to consider and approve Standalone unaudited financial results for the quarter and half year ended on 30th September, 2024. |
09 Oct, 2024 | BSE India | Certificate pursuant to Regulation 74(5) of SEBI (D&P) Regulations, 2018 for the quarter ended on 30.09.2024. |
Board Meetings
Purpose | Details | Meeting Date | Broadcast Date |
---|---|---|---|
Quarterly Results | -- | 21 Jan, 2025 | 28 Jan, 2025 |
Quarterly Results | -- | 29 Oct, 2024 | 05 Nov, 2024 |
Quarterly Results | -- | 19 Jul, 2024 | 26 Jul, 2024 |
Audited Results & Dividend | -- | 22 May, 2024 | 28 May, 2024 |
Quarterly Results | -- | 20 Jan, 2024 | 06 Feb, 2024 |
Quarterly Results | -- | 30 Oct, 2023 | 07 Nov, 2023 |
Quarterly Results | -- | 27 Jul, 2023 | 08 Aug, 2023 |
Audited Results, Dividend & A.G.M. | -- | 15 May, 2023 | 23 May, 2023 |
Quarterly Results | -- | 30 Jan, 2023 | 07 Feb, 2023 |
Buy Back of Shares | -- | 29 Nov, 2022 | 01 Dec, 2022 |
Share Holding Pattern
Owner Name | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
---|
About Jenburkt Pharmaceuticals
Jenburkt Pharmaceuticals is a Public Limited Listed company incorporated on 10/06/1985 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1985PLC036541 and registration number is 036541. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 141.97 Cr. and Equity Capital is Rs. 4.41 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1985
Managing Director
Mr. Ashish U Bhuta
NSE Symbol
--
Jenburkt Pharmaceuticals Management
Name | Designation |
---|---|
Mr. Ashish U Bhuta | Chairman & Managing Director |
Mr. Dilip H Bhuta | WholeTime Director & CFO |
Mrs. Hina R Mehta | Ind. Non-Executive Director |
Mr. Sumit A Thakkar | Ind. Non-Executive Director |
Mr. Krishnan Subharaman | Ind. Non-Executive Director |
Mr. Pankaj A Dantwala | Ind. Non-Executive Director |
Peer Comparison
Stocks | Market Cap | Market Price | 52 Week Low-High |
---|---|---|---|
Sun Pharmaceutical Industries | ₹4,03,916.05 | ₹1,683.45 ₹1,676.85(0.39%) | ₹1,376.750 - ₹1,960.200 |
Divi's Laboratories | ₹1,49,205.29 | ₹5,620.45 ₹5,667.15(-0.82%) | ₹3,350.050 - ₹6,448.750 |
Cipla | ₹1,18,065.23 | ₹1,461.90 ₹1,454.30(0.52%) | ₹1,317.600 - ₹1,702.000 |
Torrent Pharmaceuticals | ₹1,03,430.62 | ₹3,056.05 ₹3,096.50(-1.31%) | ₹2,488.000 - ₹3,589.950 |
Dr. Reddy's Laboratories | ₹92,453.48 | ₹1,107.95 ₹1,105.15(0.25%) | ₹1,093.000 - ₹1,420.200 |
FAQs on Jenburkt Pharmaceuticals
What is the share price of Jenburkt Pharmaceuticals?
The share price of Jenburkt Pharmaceuticals on 13 Mar, 2025 is ₹ 957.70.
What is 52W high and 52W low share price of Jenburkt Pharmaceuticals?
The highest and lowest 52W share prices of Jenburkt Pharmaceuticals are ₹ 1375.000 and ₹ 660.050
What is the market cap of Jenburkt Pharmaceuticals?
The market capitalization of Jenburkt Pharmaceuticals as of 13 Mar, 2025 is ₹ 422.66 Crores
What is the P/E ratio of Jenburkt Pharmaceuticals?
The current P/E ratio of Jenburkt Pharmaceuticals as of 13 Mar, 2025 is 43.95
What is the PB ratio of Jenburkt Pharmaceuticals?
The PB ratio of Jenburkt Pharmaceuticals as of 13 Mar, 2025 is 2.92
Top Gainers
₹41.02
₹34.29 (0.20%)
₹8.84
₹7.37 (0.20%)
₹6.97
₹5.81 (0.20%)
₹194.70
₹162.25 (0.20%)
Top Losers
₹13.75
₹135.15 (-0.90%)
₹9.60
₹12.00 (-0.20%)
₹9.80
₹93.55 (-0.90%)
₹0.99
₹4.77 (-0.79%)
Market Indices
Sensex
₹73,828.91
₹74,029.76 (0.00%)